Geron Corporation GERN today
announced positive clinical results from the Phase 2 trial of imetelstat, the
company's first-in-class telomerase inhibitor, in patients with essential
thrombocythemia (ET). ET is a chronic blood disorder that is representative of
a group of diseases known as myeloproliferative neoplasms (MPNs). The data,
which showed rapid and durable hematologic and molecular responses in patients
treated with imetelstat, were presented Sunday evening in an oral session at
the 54^th Annual Meeting of the American Society of Hematology (ASH) in
Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University
Hospital and University of Bern, Switzerland, and a principal investigator of
the trial. To view the presentation slides, please visit
www.geron.com/PDFs/Geron-Imetelstat-ETPh2-ASH-2012.pdf.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in